{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:09:22Z","timestamp":1776064162478,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,4,11]],"date-time":"2011-04-11T00:00:00Z","timestamp":1302480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1641-9","type":"journal-article","created":{"date-parts":[[2011,4,10]],"date-time":"2011-04-10T01:12:03Z","timestamp":1302397923000},"page":"1449-1457","source":"Crossref","is-referenced-by-count":123,"title":["Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation"],"prefix":"10.1007","volume":"68","author":[{"given":"Cristina P. R.","family":"Xavier","sequence":"first","affiliation":[]},{"given":"Cristovao F.","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Mikkel","family":"Rohde","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Pereira-Wilson","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2011,4,11]]},"reference":[{"key":"1641_CR1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1515\/BC.2004.053","volume":"385","author":"C Rupnarain","year":"2004","unstructured":"Rupnarain C, Dlamini Z, Naicker S, Bhoola K (2004) Colon cancer: genomics and apoptotic events. Biol Chem 385:449\u2013464","journal-title":"Biol Chem"},{"key":"1641_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247\u2013257","journal-title":"N Engl J Med"},{"key":"1641_CR3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3816\/CCC.2009.n.003","volume":"8","author":"S Bhushan","year":"2009","unstructured":"Bhushan S, McLeod H, Walko CM (2009) Role of pharmacogenetics as predictive biomarkers of response and\/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer 8:15\u201321","journal-title":"Clin Colorectal Cancer"},{"key":"1641_CR4","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0306-3623(98)00191-8","volume":"31","author":"RM Mader","year":"1998","unstructured":"Mader RM, Muller M, Steger GG (1998) Resistance to 5-fluorouracil. Gen Pharmacol 31:661\u2013666","journal-title":"Gen Pharmacol"},{"key":"1641_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.amjsurg.2005.11.009","volume":"191","author":"S Huerta","year":"2006","unstructured":"Huerta S, Goulet EJ, Livingston EH (2006) Colon cancer and apoptosis. Am J Surg 191:517\u2013526","journal-title":"Am J Surg"},{"key":"1641_CR6","first-page":"1470","volume":"22","author":"JM Davies","year":"2008","unstructured":"Davies JM, Goldberg RM (2008) First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park) 22:1470\u20131479","journal-title":"Oncology (Williston Park)"},{"key":"1641_CR7","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/gut.2005.073015","volume":"55","author":"R Jover","year":"2006","unstructured":"Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C (2006) Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848\u2013855","journal-title":"Gut"},{"key":"1641_CR8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00384-006-0228-0","volume":"22","author":"J Warusavitarne","year":"2007","unstructured":"Warusavitarne J, Schnitzler M (2007) The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis 22:739\u2013748","journal-title":"Int J Colorectal Dis"},{"key":"1641_CR9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/bjs.5328","volume":"93","author":"K Soreide","year":"2006","unstructured":"Soreide K, Janssen EA, Soiland H, Korner H, Baak JP (2006) Microsatellite instability in colorectal cancer. Br J Surg 93:395\u2013406","journal-title":"Br J Surg"},{"key":"1641_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/CCO.0b013e32832c94bd","volume":"21","author":"FA Sinicrope","year":"2009","unstructured":"Sinicrope FA, Sargent DJ (2009) Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369\u2013373","journal-title":"Curr Opin Oncol"},{"key":"1641_CR11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/17474124.3.1.5","volume":"3","author":"R Seruca","year":"2009","unstructured":"Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P (2009) Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. Expert Rev Gastroenterol Hepatol 3:5\u20139","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1641_CR12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V","volume":"69","author":"J Benhattar","year":"1996","unstructured":"Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190\u2013192","journal-title":"Int J Cancer"},{"key":"1641_CR13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ijc.10146","volume":"98","author":"S Violette","year":"2002","unstructured":"Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98:498\u2013504","journal-title":"Int J Cancer"},{"key":"1641_CR14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","volume":"104","author":"F Bunz","year":"1999","unstructured":"Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263\u2013269","journal-title":"J Clin Invest"},{"key":"1641_CR15","first-page":"1491","volume":"31","author":"BL Adamsen","year":"2007","unstructured":"Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491\u20131500","journal-title":"Int J Oncol"},{"key":"1641_CR16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10147-004-0406-4","volume":"9","author":"S Mori","year":"2004","unstructured":"Mori S, Ogata Y, Shirouzu K (2004) Biological features of sporadic colorectal carcinoma with high-frequency microsatellite instability: special reference to tumor proliferation and apoptosis. Int J Clin Oncol 9:322\u2013329","journal-title":"Int J Clin Oncol"},{"key":"1641_CR17","first-page":"117","volume":"1795","author":"S Hector","year":"2009","unstructured":"Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: A review. Biochim Biophys Acta 1795:117\u2013129","journal-title":"Biochim Biophys Acta"},{"key":"1641_CR18","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.bcp.2006.02.009","volume":"71","author":"BB Aggarwal","year":"2006","unstructured":"Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397\u20131421","journal-title":"Biochem Pharmacol"},{"key":"1641_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mnfr.200700326","volume":"52","author":"S Ramos","year":"2008","unstructured":"Ramos S (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol Nutr Food Res 52:507\u2013526","journal-title":"Mol Nutr Food Res"},{"key":"1641_CR20","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ddr.20276","volume":"69","author":"RA Subapriya Rajamanickam","year":"2008","unstructured":"Subapriya Rajamanickam RA (2008) Natural products and colon cancer: current status and future prospects. Drug Dev Res 69:460\u2013471","journal-title":"Drug Dev Res"},{"key":"1641_CR21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537\u2013549","journal-title":"Nat Rev Cancer"},{"key":"1641_CR22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.cr.7290262","volume":"15","author":"J Liu","year":"2005","unstructured":"Liu J, Lin A (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15:36\u201342","journal-title":"Cell Res"},{"key":"1641_CR23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","volume":"15","author":"LR Coulthard","year":"2009","unstructured":"Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA (2009) p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15:369\u2013379","journal-title":"Trends Mol Med"},{"key":"1641_CR24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2009.02.041","volume":"281","author":"CP Xavier","year":"2009","unstructured":"Xavier CP, Lima CF, Preto A, Seruca R, Fernandes-Ferreira M, Pereira-Wilson C (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Lett 281:162\u2013170","journal-title":"Cancer Lett"},{"key":"1641_CR25","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1038\/sj.onc.1204611","volume":"20","author":"J Gayet","year":"2001","unstructured":"Gayet J, Zhou XP, Duval A, Rolland S, Hoang JM, Cottu P, Hamelin R (2001) Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 20:5025\u20135032","journal-title":"Oncogene"},{"key":"1641_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00280-007-0461-4","volume":"61","author":"KW Barbour","year":"2008","unstructured":"Barbour KW, Berger FG (2008) Cell death in response to antimetabolites directed at thymidylate synthase. Cancer Chemother Pharmacol 61:189\u2013201","journal-title":"Cancer Chemother Pharmacol"},{"key":"1641_CR27","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.282.5393.1497","volume":"282","author":"F Bunz","year":"1998","unstructured":"Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497\u20131501","journal-title":"Science"},{"key":"1641_CR28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/path.2295","volume":"214","author":"A Preto","year":"2008","unstructured":"Preto A, Figueiredo J, Velho S, Ribeiro A, Soares P, Oliveira C, Seruca R (2008) BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214:320\u2013327","journal-title":"J Pathol"},{"key":"1641_CR29","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.10591","volume":"94","author":"N Itoh","year":"2002","unstructured":"Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt\/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127\u20133134","journal-title":"Cancer"},{"key":"1641_CR30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9","author":"M Osaki","year":"2004","unstructured":"Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667\u2013676","journal-title":"Apoptosis"},{"key":"1641_CR31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.sla.0000220040.66012.a9","volume":"243","author":"PG Rychahou","year":"2006","unstructured":"Rychahou PG, Jackson LN, Silva SR, Rajaraman S, Evers BM (2006) Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg 243:833\u2013842 discussion 843\u2013844","journal-title":"Ann Surg"},{"key":"1641_CR32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2005.04.007","volume":"5","author":"N Thompson","year":"2005","unstructured":"Thompson N, Lyons J (2005) Recent progress in targeting the Raf\/MEK\/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350\u2013356","journal-title":"Curr Opin Pharmacol"},{"key":"1641_CR33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","volume":"46","author":"JA McCubrey","year":"2006","unstructured":"McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D\u2019Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249\u2013279","journal-title":"Adv Enzyme Regul"},{"key":"1641_CR34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/pgmj.2006.055426","volume":"83","author":"XY Tang","year":"2007","unstructured":"Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL (2007) Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 83:338\u2013343","journal-title":"Postgrad Med J"},{"key":"1641_CR35","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3748\/wjg.v13.i10.1534","volume":"13","author":"YQ Zhang","year":"2007","unstructured":"Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG (2007) Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13:1534\u20131540","journal-title":"World J Gastroenterol"},{"key":"1641_CR36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-006-0350-2","volume":"60","author":"CZ Wang","year":"2007","unstructured":"Wang CZ, Luo X, Zhang B, Song WX, Ni M, Mehendale S, Xie JT, Aung HH, He TC, Yuan CS (2007) Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. Cancer Chemother Pharmacol 60:69\u201379","journal-title":"Cancer Chemother Pharmacol"},{"key":"1641_CR37","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1535-7163.MCT-06-0638","volume":"6","author":"R Shi","year":"2007","unstructured":"Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu J, Ong CN, Shen HM (2007) Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther 6:1338\u20131347","journal-title":"Mol Cancer Ther"},{"key":"1641_CR38","first-page":"378","volume":"43","author":"Q Hou","year":"2008","unstructured":"Hou Q (2008) Effect of staurosporine induced apoptosis of MCF7\/GFP-Bax stable cell line on Bax translocation from cytosol into mitochondria. Yao Xue Xue Bao 43:378\u2013382","journal-title":"Yao Xue Xue Bao"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1641-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1641-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1641-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:14Z","timestamp":1559038274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1641-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1641"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1641-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,11]]}}}